Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
NervGen Pharma ( (TSE:NGEN) ) has provided an update.
NervGen Pharma has announced the enrollment and dosing of the first subject in the subacute cohort of its Phase 1b/2a clinical trial for NVG-291, targeting spinal cord injury. This trial evaluates the efficacy and safety of NVG-291 in both chronic and subacute cervical spinal cord injury patients. An amendment to the trial protocol, approved by the IRB, aims to enhance enrollment and improve participant experience by revising timing and reducing assessment burdens. This development marks a significant step in NervGen’s efforts to advance NVG-291, with expected data on the chronic cohort in Q2 2025, potentially positioning the company as a leader in spinal cord injury therapeutics.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotech company focused on developing neurorestorative therapeutics. The company is dedicated to advancing treatments for spinal cord injury and has exclusive worldwide rights to NVG-291, a therapeutic peptide aimed at nervous system repair.
YTD Price Performance: -11.98%
Average Trading Volume: 70,921
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $144M
Learn more about NGEN stock on TipRanks’ Stock Analysis page.
